Femasys closes $8M in financing

Femasys (FEMY) announced the closing of $8 million in financing. This funding will provide critical resources to accelerate commercialization efforts and strengthen the company’s ability to address significant unmet needs in women’s reproductive health. To underscore this momentum, Femasys’ largest shareholder, Jorey Chernett also provided commentary on the company’s mission and recent milestones. Jorey Chernett, CEO and Founder of Clearpath and Managing Member of Pointillist Family Office, commented, “FemBloc addresses a long overdue need in women’s health. My family experienced the greatest loss when my mother passed away during a tubal ligation surgery, which was the only option available to women for permanent contraception until FemBloc. No woman should ever die from an elective procedure, and FemBloc eliminates this risk. As a long-time healthcare executive and entrepreneur, I also recognize the important work Femasys is advancing in infertility care. Their FemaSeed product fills a critical void in the market and offers another groundbreaking option for women. I am honored to support this mission, and as an experienced investor, I am confident my commitment will help bring these transformative products to women while creating meaningful value for shareholders.”